These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 15877720)

  • 1. Adolescence, schizophrenia and drug abuse: a window of vulnerability.
    van Nimwegen L; de Haan L; van Beveren N; van den Brink W; Linszen D
    Acta Psychiatr Scand Suppl; 2005; (427):35-42. PubMed ID: 15877720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adolescence, schizophrenia and drug abuse: interactive vulnerability. A hypothesis].
    van Nimwegen L; de Haan L; van Beveren N; van den Brink W; Linszen D
    Tijdschr Psychiatr; 2007; 49(3):169-78. PubMed ID: 17370223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Schizophrenia and addiction: An evaluation of the self-medication hypothesis].
    Potvin S; Stip E; Roy JY
    Encephale; 2003; 29(3 Pt 1):193-203. PubMed ID: 12876543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia.
    Potvin S; Stip E; Lipp O; Roy MA; Demers MF; Bouchard RH; Gendron A
    Am J Drug Alcohol Abuse; 2008; 34(1):75-82. PubMed ID: 18161645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comorbid schizophrenia and substance abuse.
    Green AI; Brown ES
    J Clin Psychiatry; 2006 Sep; 67(9):e08. PubMed ID: 17081075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reasons for increased substance use in psychosis.
    Gregg L; Barrowclough C; Haddock G
    Clin Psychol Rev; 2007 May; 27(4):494-510. PubMed ID: 17240501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Late adolescence and young adulthood -- their etiopathogenetic significance for schizophrenia].
    Kapfhammer HP
    Fortschr Neurol Psychiatr; 2005 Nov; 73 Suppl 1():S96-102. PubMed ID: 16270253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches.
    Green AI
    J Clin Psychiatry; 2006; 67 Suppl 7():31-5; quiz 36-7. PubMed ID: 16961422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is it time to consider comorbid substance abuse as a new indication for antipsychotic drug development?
    Awad AG
    J Psychopharmacol; 2012 Jul; 26(7):953-7. PubMed ID: 22170735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dual diagnosis psychosis and substance use disorders in adolescents--part 1].
    Meister K; Burlon M; Rietschel L; Gouzoulis-Mayfrank E; Bock T; Lambert M
    Fortschr Neurol Psychiatr; 2010 Feb; 78(2):81-9. PubMed ID: 20146152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substance abuse and the onset of schizophrenia.
    Hambrecht M; Häfner H
    Biol Psychiatry; 1996 Dec; 40(11):1155-63. PubMed ID: 8931919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substance abuse in patients with schizophrenia.
    Winklbaur B; Ebner N; Sachs G; Thau K; Fischer G
    Dialogues Clin Neurosci; 2006; 8(1):37-43. PubMed ID: 16640112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substance abuse in schizophrenia: a review.
    Buckley PF
    J Clin Psychiatry; 1998; 59 Suppl 3():26-30. PubMed ID: 9541335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substance abuse and psychosocial impairments among clients with schizophrenia.
    Schwartz RC; Hilscher RL; Hayhow P
    Am J Orthopsychiatry; 2007 Oct; 77(4):610-5. PubMed ID: 18194040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Psychobiologic risk factors and vulnerability to psychostimulants in adolescents and animal models].
    Laviola G; Adriani W; Terranova ML; Gerra G
    Ann Ist Super Sanita; 2000; 36(1):47-62. PubMed ID: 11070608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Movement disorders in patients with schizophrenia and a history of substance abuse.
    Hansen LK; Nausheen B; Hart D; Kingdon D
    Hum Psychopharmacol; 2013 Mar; 28(2):192-7. PubMed ID: 23532750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse.
    Jockers-Scherübl MC; Rentzsch J; Danker-Hopfe H; Radzei N; Schürer F; Bahri S; Hellweg R
    Neurosci Lett; 2006 Jun; 400(3):262-6. PubMed ID: 16540246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substance abuse and related diagnoses in early psychosis.
    Korkeila JA; Svirskis T; Heinimaa M; Ristkari T; Huttunen J; Ilonen T; McGlashan T; Salokangas RK
    Compr Psychiatry; 2005; 46(6):447-52. PubMed ID: 16275212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substance misuse and early psychosis.
    Tucker P
    Australas Psychiatry; 2009 Aug; 17(4):291-4. PubMed ID: 19301164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.